Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVES: To develop treat-to-target (T2T) recommendations in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).
METHODS: A systematic literature review was conducted to retrieve data on treatment targets and outcomes in GCA/PMR as well as to identify the evidence for the effectiveness of a T2T-based management approach in these diseases. Based on evidence and expert opinion, the task force (29 participants from 10 countries consisting of physicians, a healthcare professional and a patient) developed recommendations, with consensus obtained through voting. The final level of agreement was provided anonymously.
RESULTS: Five overarching principles and six-specific recommendations were formulated. Management of GCA and PMR should be based on shared decisions between patient and physician recognising the need for urgent treatment of GCA to avoid ischaemic complications, and it should aim at maximising health-related quality of life in both diseases. The treatment targets are achievement and maintenance of remission, as well as prevention of tissue ischaemia and vascular damage. Comorbidities need to be considered when assessing disease activity and selecting treatment.
CONCLUSION: These are the first T2T recommendations for GCA and PMR. Treatment targets, as well as strategies to assess, achieve and maintain these targets have been defined. The research agenda highlights the gaps in evidence and the need for future research.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
Annals of the rheumatic diseases - 83(2024), 1 vom: 02. Jan., Seite 48-57 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dejaco, Christian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological Therapy |
|---|
| Anmerkungen: |
Date Completed 04.01.2024 Date Revised 25.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/ard-2022-223429 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353347752 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353347752 | ||
| 003 | DE-627 | ||
| 005 | 20240125231831.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/ard-2022-223429 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1270.xml |
| 035 | |a (DE-627)NLM353347752 | ||
| 035 | |a (NLM)36828585 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dejaco, Christian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2024 | ||
| 500 | |a Date Revised 25.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVES: To develop treat-to-target (T2T) recommendations in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) | ||
| 520 | |a METHODS: A systematic literature review was conducted to retrieve data on treatment targets and outcomes in GCA/PMR as well as to identify the evidence for the effectiveness of a T2T-based management approach in these diseases. Based on evidence and expert opinion, the task force (29 participants from 10 countries consisting of physicians, a healthcare professional and a patient) developed recommendations, with consensus obtained through voting. The final level of agreement was provided anonymously | ||
| 520 | |a RESULTS: Five overarching principles and six-specific recommendations were formulated. Management of GCA and PMR should be based on shared decisions between patient and physician recognising the need for urgent treatment of GCA to avoid ischaemic complications, and it should aim at maximising health-related quality of life in both diseases. The treatment targets are achievement and maintenance of remission, as well as prevention of tissue ischaemia and vascular damage. Comorbidities need to be considered when assessing disease activity and selecting treatment | ||
| 520 | |a CONCLUSION: These are the first T2T recommendations for GCA and PMR. Treatment targets, as well as strategies to assess, achieve and maintain these targets have been defined. The research agenda highlights the gaps in evidence and the need for future research | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biological Therapy | |
| 650 | 4 | |a Giant Cell Arteritis | |
| 650 | 4 | |a Outcome and Process Assessment, Health Care | |
| 650 | 4 | |a Polymyalgia Rheumatica | |
| 700 | 1 | |a Kerschbaumer, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Aletaha, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Bond, Milena |e verfasserin |4 aut | |
| 700 | 1 | |a Hysa, Elvis |e verfasserin |4 aut | |
| 700 | 1 | |a Camellino, Dario |e verfasserin |4 aut | |
| 700 | 1 | |a Ehlers, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Abril, Andy |e verfasserin |4 aut | |
| 700 | 1 | |a Appenzeller, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Cid, Maria C |e verfasserin |4 aut | |
| 700 | 1 | |a Dasgupta, Bhaskar |e verfasserin |4 aut | |
| 700 | 1 | |a Duftner, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Grayson, Peter C |e verfasserin |4 aut | |
| 700 | 1 | |a Hellmich, Bernhard |e verfasserin |4 aut | |
| 700 | 1 | |a Hočevar, Alojzija |e verfasserin |4 aut | |
| 700 | 1 | |a Kermani, Tanaz A |e verfasserin |4 aut | |
| 700 | 1 | |a Matteson, Eric L |e verfasserin |4 aut | |
| 700 | 1 | |a Mollan, Susan P |e verfasserin |4 aut | |
| 700 | 1 | |a Neill, Lorna |e verfasserin |4 aut | |
| 700 | 1 | |a Ponte, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Salvarani, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Sattui, Sebastian Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Wolfgang A |e verfasserin |4 aut | |
| 700 | 1 | |a Seo, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Smolen, Josef S |e verfasserin |4 aut | |
| 700 | 1 | |a Thiel, Jens |e verfasserin |4 aut | |
| 700 | 1 | |a Toro-Gutiérrez, Carlos Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Whitlock, Madeline |e verfasserin |4 aut | |
| 700 | 1 | |a Buttgereit, Frank |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 83(2024), 1 vom: 02. Jan., Seite 48-57 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2024 |g number:1 |g day:02 |g month:01 |g pages:48-57 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/ard-2022-223429 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2024 |e 1 |b 02 |c 01 |h 48-57 | ||